LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Non-Profit & Charity
• Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

inhibitor, article, phase, patients, gsk, mek, study, cancer, google, scholar, combination, solid, tumors, pubmed, trametinib, advanced, oral, cas, doseescalation, clinical, usa, bedard, pik, gdc, clin, research, trial, oncol, grilleyolson, dose, dosing, trials, privacy, cookies, content, cartee, intermittent, response, due, access, akt, drug, kinase, res, oncology, glaxosmithkline, data, information, publish, search,

Topics {✒️}

/nm/journal/v14/n9/suppinfo/nm month download article/chapter pan-pi3k/mtor inhibitor oral pan-pi3k bkm120 pi3k/mtor inhibitor gsk2126458 identifying genotype-dependent efficacy pi3k/pten/akt pathways bayesian dose-finding design clinical trials phase ib study clinical trial access combination trials full article pdf dose-escalation trial gi-related toxicities advanced solid tumors received research funding national research committee pi3k/mtor inhibitor privacy choices/manage cookies related subjects allosteric akt inhibitor pi3k inhibitor pictilisib metastatic solid tumors bayesian dose finding circulating mutant dna akt inhibitor ipatasertib akt inhibitor afuresertib dose-escalation study zone-based 3 + 3 design pi3k inhibitor gdc-0941 ras/raf/pi3k mapk/erk kinase oxford ox2 6dp oxford ox5 1gb irccs scientific institute received travel funding mek inhibitor cobimetinib mek inhibitor trametinib mapk-pathway inhibition breast cancer models breast cancer cells article grilley-olson phosphatidylinositol 3-kinase inhibitors medical oncology 1q mek inhibitor gdc-0973 article investigational intermittent dosing cohort maximum tolerated dose european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
         description: Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or intermittent) and trametinib following a zone-based 3 + 3 design to determine the maximum tolerated dose (MTD). Assessments included monitoring for adverse events and response, and evaluating pharmacokinetic (PK) measures. Archival tissue and circulating free DNA samples were collected to assess biomarkers of response in the PI3K and RAS pathways. Results 57 patients were enrolled onto the continuous dosing cohort and 12 patients onto an intermittent BID dosing cohort. Two MTDs were established for the continuous daily dosing: 2 mg of GSK458 with 1.0 mg of trametinib or 1.0 mg of GSK458 with 1.5 mg of trametinib; no MTD was determined in the intermittent dosing cohort. The most frequent adverse events were rash (74 %) and diarrhea (61 %). Dose interruptions due to adverse events occurred in 42 % of patients. No significant PK interaction was observed. One patient achieved partial response and 12 patients had stable disease >16 weeks. Mutations in RAS/RAF/PI3K were detected in 70 % of patients, but no pattern emerged between response and mutational status. Conclusion GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities. Responses were minimal, despite enrichment for PI3K/RAS pathway driven tumors, which may be due to overlapping toxicities precluding sufficient dose exposure.
         datePublished:2016-07-23T00:00:00Z
         dateModified:2016-07-23T00:00:00Z
         pageStart:740
         pageEnd:749
         sameAs:https://doi.org/10.1007/s10637-016-0377-0
         keywords:
            Trametinib
            GSK2126458
            MEK inhibitor
            PI3K inhibitor
            Phase I clinical trial
            Oncology
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig3_HTML.gif
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:34
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:J. E. Grilley-Olson
               affiliation:
                     name:University of North Carolina Lineberger Comprehensive Cancer Center
                     address:
                        name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:P. L. Bedard
               affiliation:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                     address:
                        name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Fasolo
               affiliation:
                     name:IRCCS Scientific Institute
                     address:
                        name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Cornfeld
               affiliation:
                     name:GlaxoSmithKline Plc
                     address:
                        name:GlaxoSmithKline Plc, Collegeville, USA
                        type:PostalAddress
                     type:Organization
                     name:RTP
                     address:
                        name:RTP, Durham, USA
                        type:PostalAddress
                     type:Organization
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L. Cartee
               affiliation:
                     name:GlaxoSmithKline Plc
                     address:
                        name:GlaxoSmithKline Plc, Collegeville, USA
                        type:PostalAddress
                     type:Organization
                     name:RTP
                     address:
                        name:RTP, Durham, USA
                        type:PostalAddress
                     type:Organization
                     name:UNC Lineberger Comprehensive Cancer Center
                     address:
                        name:UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. R. Abdul Razak
               affiliation:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                     address:
                        name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L.-A. Stayner
               affiliation:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                     address:
                        name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Y. Wu
               affiliation:
                     name:GlaxoSmithKline Plc
                     address:
                        name:GlaxoSmithKline Plc, Collegeville, USA
                        type:PostalAddress
                     type:Organization
                     name:RTP
                     address:
                        name:RTP, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Greenwood
               affiliation:
                     name:GlaxoSmithKline Plc
                     address:
                        name:GlaxoSmithKline Plc, Collegeville, USA
                        type:PostalAddress
                     type:Organization
                     name:RTP
                     address:
                        name:RTP, Durham, USA
                        type:PostalAddress
                     type:Organization
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Singh
               affiliation:
                     name:GlaxoSmithKline Plc
                     address:
                        name:GlaxoSmithKline Plc, Collegeville, USA
                        type:PostalAddress
                     type:Organization
                     name:RTP
                     address:
                        name:RTP, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. B. Lee
               affiliation:
                     name:University of North Carolina Lineberger Comprehensive Cancer Center
                     address:
                        name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Bendell
               affiliation:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                     address:
                        name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. A. Burris
               affiliation:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                     address:
                        name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Del Conte
               affiliation:
                     name:IRCCS Scientific Institute
                     address:
                        name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Sessa
               affiliation:
                     name:IRCCS Scientific Institute
                     address:
                        name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. R. Infante
               affiliation:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                     address:
                        name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
      description: Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or intermittent) and trametinib following a zone-based 3 + 3 design to determine the maximum tolerated dose (MTD). Assessments included monitoring for adverse events and response, and evaluating pharmacokinetic (PK) measures. Archival tissue and circulating free DNA samples were collected to assess biomarkers of response in the PI3K and RAS pathways. Results 57 patients were enrolled onto the continuous dosing cohort and 12 patients onto an intermittent BID dosing cohort. Two MTDs were established for the continuous daily dosing: 2 mg of GSK458 with 1.0 mg of trametinib or 1.0 mg of GSK458 with 1.5 mg of trametinib; no MTD was determined in the intermittent dosing cohort. The most frequent adverse events were rash (74 %) and diarrhea (61 %). Dose interruptions due to adverse events occurred in 42 % of patients. No significant PK interaction was observed. One patient achieved partial response and 12 patients had stable disease >16 weeks. Mutations in RAS/RAF/PI3K were detected in 70 % of patients, but no pattern emerged between response and mutational status. Conclusion GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities. Responses were minimal, despite enrichment for PI3K/RAS pathway driven tumors, which may be due to overlapping toxicities precluding sufficient dose exposure.
      datePublished:2016-07-23T00:00:00Z
      dateModified:2016-07-23T00:00:00Z
      pageStart:740
      pageEnd:749
      sameAs:https://doi.org/10.1007/s10637-016-0377-0
      keywords:
         Trametinib
         GSK2126458
         MEK inhibitor
         PI3K inhibitor
         Phase I clinical trial
         Oncology
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-016-0377-0/MediaObjects/10637_2016_377_Fig3_HTML.gif
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:34
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J. E. Grilley-Olson
            affiliation:
                  name:University of North Carolina Lineberger Comprehensive Cancer Center
                  address:
                     name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:P. L. Bedard
            affiliation:
                  name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                  address:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Fasolo
            affiliation:
                  name:IRCCS Scientific Institute
                  address:
                     name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Cornfeld
            affiliation:
                  name:GlaxoSmithKline Plc
                  address:
                     name:GlaxoSmithKline Plc, Collegeville, USA
                     type:PostalAddress
                  type:Organization
                  name:RTP
                  address:
                     name:RTP, Durham, USA
                     type:PostalAddress
                  type:Organization
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L. Cartee
            affiliation:
                  name:GlaxoSmithKline Plc
                  address:
                     name:GlaxoSmithKline Plc, Collegeville, USA
                     type:PostalAddress
                  type:Organization
                  name:RTP
                  address:
                     name:RTP, Durham, USA
                     type:PostalAddress
                  type:Organization
                  name:UNC Lineberger Comprehensive Cancer Center
                  address:
                     name:UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. R. Abdul Razak
            affiliation:
                  name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                  address:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L.-A. Stayner
            affiliation:
                  name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
                  address:
                     name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Y. Wu
            affiliation:
                  name:GlaxoSmithKline Plc
                  address:
                     name:GlaxoSmithKline Plc, Collegeville, USA
                     type:PostalAddress
                  type:Organization
                  name:RTP
                  address:
                     name:RTP, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Greenwood
            affiliation:
                  name:GlaxoSmithKline Plc
                  address:
                     name:GlaxoSmithKline Plc, Collegeville, USA
                     type:PostalAddress
                  type:Organization
                  name:RTP
                  address:
                     name:RTP, Durham, USA
                     type:PostalAddress
                  type:Organization
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Singh
            affiliation:
                  name:GlaxoSmithKline Plc
                  address:
                     name:GlaxoSmithKline Plc, Collegeville, USA
                     type:PostalAddress
                  type:Organization
                  name:RTP
                  address:
                     name:RTP, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. B. Lee
            affiliation:
                  name:University of North Carolina Lineberger Comprehensive Cancer Center
                  address:
                     name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Bendell
            affiliation:
                  name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                  address:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. A. Burris
            affiliation:
                  name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                  address:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Del Conte
            affiliation:
                  name:IRCCS Scientific Institute
                  address:
                     name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Sessa
            affiliation:
                  name:IRCCS Scientific Institute
                  address:
                     name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. R. Infante
            affiliation:
                  name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
                  address:
                     name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:34
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of North Carolina Lineberger Comprehensive Cancer Center
      address:
         name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
         type:PostalAddress
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
      address:
         name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
         type:PostalAddress
      name:IRCCS Scientific Institute
      address:
         name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
         type:PostalAddress
      name:GlaxoSmithKline Plc
      address:
         name:GlaxoSmithKline Plc, Collegeville, USA
         type:PostalAddress
      name:RTP
      address:
         name:RTP, Durham, USA
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:GlaxoSmithKline Plc
      address:
         name:GlaxoSmithKline Plc, Collegeville, USA
         type:PostalAddress
      name:RTP
      address:
         name:RTP, Durham, USA
         type:PostalAddress
      name:UNC Lineberger Comprehensive Cancer Center
      address:
         name:UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
         type:PostalAddress
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
      address:
         name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
         type:PostalAddress
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
      address:
         name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
         type:PostalAddress
      name:GlaxoSmithKline Plc
      address:
         name:GlaxoSmithKline Plc, Collegeville, USA
         type:PostalAddress
      name:RTP
      address:
         name:RTP, Durham, USA
         type:PostalAddress
      name:GlaxoSmithKline Plc
      address:
         name:GlaxoSmithKline Plc, Collegeville, USA
         type:PostalAddress
      name:RTP
      address:
         name:RTP, Durham, USA
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:GlaxoSmithKline Plc
      address:
         name:GlaxoSmithKline Plc, Collegeville, USA
         type:PostalAddress
      name:RTP
      address:
         name:RTP, Durham, USA
         type:PostalAddress
      name:University of North Carolina Lineberger Comprehensive Cancer Center
      address:
         name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
         type:PostalAddress
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
      address:
         name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
         type:PostalAddress
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
      address:
         name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
         type:PostalAddress
      name:IRCCS Scientific Institute
      address:
         name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
         type:PostalAddress
      name:IRCCS Scientific Institute
      address:
         name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
         type:PostalAddress
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
      address:
         name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J. E. Grilley-Olson
      affiliation:
            name:University of North Carolina Lineberger Comprehensive Cancer Center
            address:
               name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:P. L. Bedard
      affiliation:
            name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
            address:
               name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:A. Fasolo
      affiliation:
            name:IRCCS Scientific Institute
            address:
               name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
               type:PostalAddress
            type:Organization
      name:M. Cornfeld
      affiliation:
            name:GlaxoSmithKline Plc
            address:
               name:GlaxoSmithKline Plc, Collegeville, USA
               type:PostalAddress
            type:Organization
            name:RTP
            address:
               name:RTP, Durham, USA
               type:PostalAddress
            type:Organization
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:L. Cartee
      affiliation:
            name:GlaxoSmithKline Plc
            address:
               name:GlaxoSmithKline Plc, Collegeville, USA
               type:PostalAddress
            type:Organization
            name:RTP
            address:
               name:RTP, Durham, USA
               type:PostalAddress
            type:Organization
            name:UNC Lineberger Comprehensive Cancer Center
            address:
               name:UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
               type:PostalAddress
            type:Organization
      name:A. R. Abdul Razak
      affiliation:
            name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
            address:
               name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:L.-A. Stayner
      affiliation:
            name:University Health Network- Princess Margaret Cancer Centre and University of Toronto
            address:
               name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Y. Wu
      affiliation:
            name:GlaxoSmithKline Plc
            address:
               name:GlaxoSmithKline Plc, Collegeville, USA
               type:PostalAddress
            type:Organization
            name:RTP
            address:
               name:RTP, Durham, USA
               type:PostalAddress
            type:Organization
      name:R. Greenwood
      affiliation:
            name:GlaxoSmithKline Plc
            address:
               name:GlaxoSmithKline Plc, Collegeville, USA
               type:PostalAddress
            type:Organization
            name:RTP
            address:
               name:RTP, Durham, USA
               type:PostalAddress
            type:Organization
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:R. Singh
      affiliation:
            name:GlaxoSmithKline Plc
            address:
               name:GlaxoSmithKline Plc, Collegeville, USA
               type:PostalAddress
            type:Organization
            name:RTP
            address:
               name:RTP, Durham, USA
               type:PostalAddress
            type:Organization
      name:C. B. Lee
      affiliation:
            name:University of North Carolina Lineberger Comprehensive Cancer Center
            address:
               name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
               type:PostalAddress
            type:Organization
      name:J. Bendell
      affiliation:
            name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
            address:
               name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
               type:PostalAddress
            type:Organization
      name:H. A. Burris
      affiliation:
            name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
            address:
               name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
               type:PostalAddress
            type:Organization
      name:G. Del Conte
      affiliation:
            name:IRCCS Scientific Institute
            address:
               name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
               type:PostalAddress
            type:Organization
      name:C. Sessa
      affiliation:
            name:IRCCS Scientific Institute
            address:
               name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
               type:PostalAddress
            type:Organization
      name:J. R. Infante
      affiliation:
            name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC
            address:
               name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
      name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
      name:GlaxoSmithKline Plc, Collegeville, USA
      name:RTP, Durham, USA
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:GlaxoSmithKline Plc, Collegeville, USA
      name:RTP, Durham, USA
      name:UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
      name:University Health Network- Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
      name:GlaxoSmithKline Plc, Collegeville, USA
      name:RTP, Durham, USA
      name:GlaxoSmithKline Plc, Collegeville, USA
      name:RTP, Durham, USA
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:GlaxoSmithKline Plc, Collegeville, USA
      name:RTP, Durham, USA
      name:Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
      name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
      name:Unità Nuovi Farmaci e Terapie Innovative Dept. Medical Oncology 1Q-A Ospedale San Raffaele, IRCCS Scientific Institute, Milan, Italy
      name:Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(106)

• Learn how profitable https://www.springernature.com/gp/authors is on a monthly basis
• Get to know what's the income of https://link.springernature.com/home/
• Monthly income for https://order.springer.com/public/cart
• How much does https://submission.nature.com/new-submission/10637/3 pull in?
• See how much https://www.springernature.com/gp/librarians/licensing/agc/journals makes per month
• What's the financial intake of https://doi.org/10.1016%2Fj.advenzreg.2006.01.004?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Roles%20of%20the%20RAF%2FMEK%2FERK%20and%20PI3K%2FPTEN%2FAKT%20pathways%20in%20malignant%20transformation%20and%20drug%20resistance&journal=Adv%20Enzym%20Regul&doi=10.1016%2Fj.advenzreg.2006.01.004&volume=46&issue=1&pages=249-279&publication_year=2006&author=McCubrey%2CJA&author=Steelman%2CLS&author=Abrams%2CSL&author=Lee%2CJT&author=Chang%2CF&author=Bertrand%2CFE&author=Navolanic%2CPM&author=Terrian%2CDM&author=Franklin%2CRA&author=D%E2%80%99Assoro%2CAB
• What's the monthly income of https://doi.org/10.1038%2Fnm.1890?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19029981 have?
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683415 produce monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Effective%20use%20of%20PI3K%20and%20MEK%20inhibitors%20to%20treat%20mutant%20Kras%20G12D%20and%20PIK3CA%20H1047R%20murine%20lung%20cancers&journal=Nat%20Med&doi=10.1038%2Fnm.1890&volume=14&issue=12&pages=1351-1356&publication_year=2008&author=Engelman%2CJA&author=Chen%2CL&author=Tan%2CX&author=Crosby%2CK&author=Guimaraes%2CAR&author=Upadhyay%2CR&author=Maira%2CM&author=McNamara%2CK&author=Perera%2CSA&author=Song%2CY bring in each month?
• Explore the financials of https://doi.org/10.1158%2F1078-0432.CCR-09-0317
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19567590 pull in?
• How much income does http://scholar.google.com/scholar_lookup?&title=In%20vivo%20antitumor%20activity%20of%20MEK%20and%20phosphatidylinositol%203-kinase%20inhibitors%20in%20basal-like%20breast%20cancer%20models&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-0317&volume=15&issue=14&pages=4649-4664&publication_year=2009&author=Hoeflich%2CKP&author=O%27Brien%2CC&author=Boyd%2CZ&author=Cavet%2CG&author=Guerrero%2CS&author=Jung%2CK&author=Januario%2CT&author=Savage%2CH&author=Punnoose%2CE&author=Truong%2CT have?
• How much revenue does https://doi.org/10.1158%2F0008-5472.CAN-08-3389 generate?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19147570's financial summary
• How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737189 make?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Basal%20subtype%20and%20MAPK%2FERK%20kinase%20%28MEK%29-phosphoinositide%203-kinase%20feedback%20signaling%20determine%20susceptibility%20of%20breast%20cancer%20cells%20to%20MEK%20inhibition&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-08-3389&volume=69&issue=2&pages=565-572&publication_year=2009&author=Mirzoeva%2COK&author=Das%2CD&author=Heiser%2CLM&author=Bhattacharya%2CS&author=Siwak%2CD&author=Gendelman%2CR&author=Bayani%2CN&author=Wang%2CNJ&author=Neve%2CRM&author=Guan%2CY make?
• https://doi.org/10.1016%2FS1470-2045%2812%2970270-X's total income per month
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22805291?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Safety%2C%20pharmacokinetic%2C%20pharmacodynamic%2C%20and%20efficacy%20data%20for%20the%20oral%20MEK%20inhibitor%20trametinib%3A%20a%20phase%201%20dose-escalation%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2812%2970270-X&volume=13&issue=8&pages=773-781&publication_year=2012&author=Infante%2CJR&author=Fecher%2CLA&author=Falchook%2CGS&author=Nallapareddy%2CS&author=Gordon%2CMS&author=Becerra%2CC&author=DeMarini%2CDJ&author=Cox%2CDS&author=Xu%2CY&author=Morris%2CSR
• How much does https://doi.org/10.1016%2Fj.ejca.2008.10.026 net monthly?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19097774 generate?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2008.10.026&volume=45&issue=2&pages=228-247&publication_year=2009&author=Eisenhauer%2CE&author=Therasse%2CP&author=Bogaerts%2CJ&author=Schwartz%2CL&author=Sargent%2CD&author=Ford%2CR&author=Dancey%2CJ&author=Arbuck%2CS&author=Gwyther%2CS&author=Mooney%2CM
• Income figures for http://www.nature.com/nm/journal/v14/n9/suppinfo/nm.1789_S1.html
• How much income does https://doi.org/10.1038%2Fnm.1789 have?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18670422?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Circulating%20mutant%20DNA%20to%20assess%20tumor%20dynamics&journal=Nat%20Med&doi=10.1038%2Fnm.1789&volume=14&issue=9&pages=985-990&publication_year=2008&author=Diehl%2CF&author=Schmidt%2CK&author=Choti%2CMA&author=Romans%2CK&author=Goodman%2CS&author=Li%2CM&author=Thornton%2CK&author=Agrawal%2CN&author=Sokoll%2CL&author=Szabo%2CSA&author=Kinzler%2CKW&author=Vogelstein%2CB&author=Diaz%20Jr%2CLA?
• How much profit does https://doi.org/10.1111%2Fj.1467-9876.2010.00710_1.x make?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Bayesian%20dose%20finding%20in%20oncology%20for%20drug%20combinations%20by%20copula%20regression&journal=J%20R%20Stat%20Soc%3A%20Series%20C%20%28Applied%20Statistics%29&doi=10.1111%2Fj.1467-9876.2010.00710_1.x&volume=59&issue=3&pages=543-544&publication_year=2010&author=Gasparini%2CM&author=Bailey%2CS&author=Neuenschwander%2CB?
• Earnings of https://doi.org/10.1002/pst.1621
• How much does https://doi.org/10.1002%2Fpst.1621 make?
• What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24828456?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=A%20Bayesian%20dose-finding%20design%20for%20drug%20combination%20clinical%20trials%20based%20on%20the%20logistic%20model&journal=Pharm%20Stat&doi=10.1002%2Fpst.1621&volume=13&issue=4&pages=247-257&publication_year=2014&author=Riviere%2CMK&author=Yuan%2CY&author=Dubois%2CF&author=Zohar%2CS?
• Profit of https://doi.org/10.1002/sim.2106
• What is the earnings of https://doi.org/10.1002%2Fsim.2106?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15909291?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Flexible%20Bayesian%20methods%20for%20cancer%20phase%20I%20clinical%20trials.%20Dose%20escalation%20with%20overdose%20control&journal=Stat%20Med&doi=10.1002%2Fsim.2106&volume=24&issue=14&pages=2183-2196&publication_year=2005&author=Tighiouart%2CM&author=Rogatko%2CA&author=Babb%2CJS make?
• Earnings of http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%20dose-escalation%20study%20of%20oral%20MK-2206%20%28allosteric%20AKT%20inhibitor%29%20with%20oral%20selumetinib%20%28AZD6244%3B%20MEK%20inhibitor%29%20in%20patients%20with%20advanced%20or%20metastatic%20solid%20tumors&journal=J%20Clin%20Oncol&volume=29&publication_year=2011&author=Tolcher%2CA&author=Baird%2CR&author=Patnaik%2CA&author=Moreno%20Garcia%2CV&author=Papadopoulos%2CK&author=Garrett%2CC&author=Olmos%2CD&author=Shannon%2CK&author=Zazulina%2CV&author=Eubin%2CE
• How much money does http://scholar.google.com/scholar_lookup?&title=Clinical%20combination%20of%20the%20MEK%20inhibitor%20GDC-0973%20and%20the%20PI3K%20inhibitor%20GDC-0941%3A%20A%20first-in-human%20phase%20Ib%20study%20testing%20daily%20and%20intermittent%20dosing%20schedules%20in%20patients%20with%20advanced%20solid%20tumors&journal=J%20Clin%20Oncol&volume=29&issue=15%20suppl&publication_year=2011&author=Shapiro%2CG&author=LoRusso%2CP&author=Kwak%2CE&author=Cleary%2CJ&author=Musib%2CL&author=Jones%2CC&author=Crespigny%2CA&author=Belvin%2CM&author=McKenzie%2CM&author=Gates%2CM make?
• How much does https://doi.org/10.1200%2FJCO.2010.32.4145 net monthly?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Phase%20I%20dose-escalation%20of%20the%20oral%20MEK1%2F2%20inhibitor%20GSK1120212%20%28GSK212%29%20dosed%20in%20combination%20with%20the%20oral%20AKT%20inhibitor%20GSK2141795%20%28GSK795%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2010.32.4145&volume=29&publication_year=2011&author=Kurzrock%2CR&author=Patnaik%2CA&author=Rosenstein%2CL&author=Fu%2CS&author=Papadopoulos%2CK&author=Smith%2CD&author=Falchook%2CG&author=Chambers%2CG&author=Gauvin%2CJ&author=Naing%2CA generate?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25417902 bring in?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20the%20MEK%20inhibitor%20trametinib%20in%20combination%20with%20the%20AKT%20inhibitor%20afuresertib%20in%20patients%20with%20solid%20tumors%20and%20multiple%20myeloma&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-014-2615-5&volume=75&issue=1&pages=183-189&publication_year=2015&author=Tolcher%2CAW&author=Patnaik%2CA&author=Papadopoulos%2CKP&author=Rasco%2CDW&author=Becerra%2CCR&author=Allred%2CAJ&author=Orford%2CK&author=Aktan%2CG&author=Ferron-Brady%2CG&author=Ibrahim%2CN produce monthly?
• What is the monthly revenue of https://doi.org/10.1158%2F0008-5472.CAN-11-1515?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22084396 rake in every month?
• How much money does http://scholar.google.com/scholar_lookup?&title=Intermittent%20administration%20of%20MEK%20inhibitor%20GDC-0973%20plus%20PI3K%20inhibitor%20GDC-0941%20triggers%20robust%20apoptosis%20and%20tumor%20growth%20inhibition&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-11-1515&volume=72&issue=1&pages=210-219&publication_year=2012&author=Hoeflich%2CKP&author=Merchant%2CM&author=Orr%2CC&author=Chan%2CJ&author=Den%20Otter%2CD&author=Berry%2CL&author=Kasman%2CI&author=Koeppen%2CH&author=Rice%2CK&author=Yang%2CN-Y generate?
• Get to know https://doi.org/10.1158%2F1078-0432.CCR-14-0521's earnings
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25125258
• How much income does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135521 have?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Design%20of%20Phase%20I%20Combination%20Trials%3A%20Recommendations%20of%20the%20Clinical%20Trial%20Design%20Task%20Force%20of%20the%20NCI%20Investigational%20Drug%20Steering%20Committee&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-0521&volume=20&issue=16&pages=4210-4217&publication_year=2014&author=Paller%2CCJ&author=Bradbury%2CPA&author=Ivy%2CSP&author=Seymour%2CL&author=LoRusso%2CPM&author=Baker%2CL&author=Rubinstein%2CL&author=Huang%2CE&author=Collyar%2CD&author=Groshen%2CS
• What's the financial gain of https://doi.org/10.1158/1078-0432.ccr-14-1814?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25500057 rake in every month?
• Profit of http://scholar.google.com/scholar_lookup?&title=A%20Phase%20Ib%20Dose-Escalation%20Study%20of%20the%20Oral%20Pan-PI3K%20Inhibitor%20Buparlisib%20%28BKM120%29%20in%20Combination%20with%20the%20Oral%20MEK1%2F2%20Inhibitor%20Trametinib%20%28GSK1120212%29%20in%20Patients%20with%20Selected%20Advanced%20Solid%20Tumors&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.ccr-14-1814&publication_year=2014&author=Bedard%2CPL&author=Tabernero%2CJ&author=Janku%2CF&author=Wainberg%2CZA&author=Paz-Ares%2CL&author=Vansteenkiste%2CJ&author=Van%20Cutsem%2CE&author=P%C3%A9rez-Garc%C3%ADa%2CJ&author=Stathis%2CA&author=Britten%2CCD&author=Le%2CN&author=Carter%2CK&author=Demanse%2CD&author=Csonka%2CD&author=Peters%2CM&author=Zubel%2CA&author=Nauwelaerts%2CH&author=Sessa%2CC
• What's the monthly income of https://citation-needed.springer.com/v2/references/10.1007/s10637-016-0377-0?format=refman&flavour=references?
• What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20E.%20Grilley-Olson?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20E.%20Grilley-Olson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=P.%20L.%20Bedard
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22P.%20L.%20Bedard%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20Fasolo have monthly?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20Fasolo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20Cornfeld's gross income?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20Cornfeld%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=L.%20Cartee?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22L.%20Cartee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
• Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20R.%20Abdul%20Razak
• What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20R.%20Abdul%20Razak%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=L.-A.%20Stayner?
• What are the total earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22L.-A.%20Stayner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Y.%20Wu
• Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Y.%20Wu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Get to know https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R.%20Greenwood's earnings
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R.%20Greenwood%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R.%20Singh generate monthly?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R.%20Singh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20B.%20Lee earn?
• How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20B.%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20Bendell
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20Bendell%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
• How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=H.%20A.%20Burris?
• What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22H.%20A.%20Burris%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
• What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=G.%20Del%20Conte?
• What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22G.%20Del%20Conte%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
• What's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Sessa?
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Sessa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20R.%20Infante?
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20R.%20Infante%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What's the monthly money flow for https://s100.copyright.com/AppDispatchServlet?title=A%20phase%20Ib%20dose-escalation%20study%20of%20the%20MEK%20inhibitor%20trametinib%20in%20combination%20with%20the%20PI3K%2FmTOR%20inhibitor%20GSK2126458%20in%20patients%20with%20advanced%20solid%20tumors&author=J.%20E.%20Grilley-Olson%20et%20al&contentID=10.1007%2Fs10637-016-0377-0©right=Springer%20Science%2BBusiness%20Media%20New%20York&publication=0167-6997&publicationDate=2016-07-23&publisherName=SpringerNature&orderBeanReset=true?
• How much does https://crossmark.crossref.org/dialog/?doi=10.1007/s10637-016-0377-0 rake in every month?
• What's the income generated by https://citation-needed.springer.com/v2/references/10.1007/s10637-016-0377-0?format=refman&flavour=citation each month?
• How much money does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral generate?
• Monthly income for https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• How much does https://www.springernature.com/gp/products gross monthly?
• What is the earnings of https://www.springernature.com/gp/librarians?
• How much does https://www.springernature.com/gp/societies rake in every month?
• What's the financial gain of https://www.springernature.com/gp/partners?
• Discover the revenue of https://www.springer.com/
• How much profit does https://www.nature.com/ generate?
• How much money does https://www.biomedcentral.com/ make?
• What's the financial intake of https://www.palgrave.com/?
• Find out how much https://www.apress.com/ earns monthly
• What are the earnings of https://www.springernature.com/gp/legal/ccpa?
• See how much https://www.springernature.com/gp/info/accessibility makes per month
• Get to know what's the income of https://support.springernature.com/en/support/home
• What's the monthly income of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
• How much does https://www.springernature.com/ rake in every month?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref